Puma Biotechnology, Inc. (PBYI)

4,6200 -0,2400 (-4,94%) Alla chiusura: 04:00PM EDT

Puma Biotechnology, Inc.

10880 Wilshire Boulevard
Suite 2150
Los Angeles, CA 90024
United States
424-248-6500
https://www.pumabiotechnology.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 185

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Alan H. Auerbach	Founder, Chairman, President, CEO & Secretary	1,3M	N/D	1970
Mr. Maximo F. Nougues	CFO & Principal Accounting Officer	716,2k	N/D	1969
Dr. Alvin F. Wong Pharm.d.	Chief Scientific Officer	714,24k	N/D	1953
Mr. Douglas Hunt B.Sc., FRAPS	Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer	598k	N/D	1965
Mr. Jeffrey Jerome Ludwig	Chief Commercial Officer	792,57k	N/D	1966
Mr. Mariann Ohanesian	Senior Director of Investor Relations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Governance aziendale

L'ISS Governance QualityScore di Puma Biotechnology, Inc. al 1 maggio 2024 è 5. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 6; diritti degli azionisti: 3; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.